Evidence map›Paper›PMID 37236997›Full record

ArticleScientific reports2023

Theoretical investigation of dynamics and concurrence of entangled [Formula: see text] and anti-[Formula: see text] symmetric polarized photons.

Javed Akram, Chao Zheng

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Javed AkrameleQtron GmbH, Martinshardt 19, 57074 Siegen, Germany.
Chao ZhengDepartment of Physics, College of Science, North China University of Technology, Beijing, 100144 China.

Funding

Natural Science Foundation of Beijing Municipality 1222020
6 · The paper itself

Abstract

Non-Hermitian systems with parity-time [Formula: see text] symmetry and anti-parity-time [Formula: see text] symmetry have exceptional points (EPs) resulting from eigenvector co-coalescence with exceptional properties. In the quantum and classical domains, higher-order EPs for [Formula: see text] symmetry and [Formula: see text]-symmetry systems have been proposed and realized. Both two-qubits [Formula: see text]-[Formula: see text] and [Formula: see text]-[Formula: see text] symmetric systems have seen an increase in recent years, especially in the dynamics of quantum entanglement. However, to our knowledge, neither theoretical nor experimental investigations have been conducted for the dynamics of two-qubits entanglement in the [Formula: see text]-[Formula: see text] symmetric system. We investigate the [Formula: see text]-[Formula: see text] dynamics for the first time. Moreover, we examine the impact of different initial Bell-state conditions on entanglement dynamics in [Formula: see text]-[Formula: see text], [Formula: see text]-[Formula: see text] and [Formula: see text]-[Formula: see text] symmetric systems. Additionally, we conduct a comparative study of entanglement dynamics in the [Formula: see text]-[Formula: see text] symmetrical system, [Formula: see text]-[Formula: see text] symmetrical system, and [Formula: see text]-[Formula: see text] symmetrical systems in order to learn more about non-Hermitian quantum systems and their environments. Entangled qubits evolve in a [Formula: see text]-[Formula: see text] symmetric unbroken regime, the entanglement oscillates with two different oscillation frequencies, and the entanglement is well preserved for a long period of time for the case when non-Hermitian parts of both qubits are taken quite away from the exceptional points.

Identifiers

PMID37236997
PMCPMC10220064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.